<p><strong>Diarrhea</strong>: Abemaciclib can cause severe cases of diarrhea, associated with dehydration and infection. Instruct patients at the first sign of loose stools to initiate antidiarrheal therapy, increase oral fluids, and notify their healthcare provider.<br />
<br />
<strong>Neutropenia</strong>: Monitor complete blood counts prior to the start of Abemaciclib therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.<br />
<br />
<strong>Interstitial Lung Disease (ILD)/Pneumonitis</strong>: Severe and fatal cases of ILD/pneumonitis have been reported. Monitor for clinical symptoms or radiological changes indicative of ILD/pneumonitis. Permanently discontinue Abemaciclib in all patients with Grade 3 or 4 ILD or pneumonitis.<br />
<br />
<strong>Hepatotoxicity</strong>: Increases in serum transaminase levels have been observed. Perform liver function tests (LFTs) before initiating treatment with Abemaciclib. Monitor LFTs every two weeks for the first two months, monthly for the next 2 months, and as clinically indicated.<br />
<br />
<strong>Venous Thromboembolism</strong>: Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate.<br />
<br />
<strong>Embryo-Fetal Toxicity</strong>: Can cause fetal harm. Advise patients of potential</p>